Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2023-04-05 Director's Dealing
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-04-05 English
10-K
Annual Report FY 2022
2023-03-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing by ADMA Biologics, Inc. which serves as a notice that the company has issued a press release regarding its financial results. Per the 'Menu vs Meal' rule, since this document is a short regulatory filing (Form 8-K) that merely announces and attaches a press release (Exhibit 99.1) rather than containing the full financial report itself, it is classified as a Regulatory Filing (RNS).
2023-03-23 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on executive compensation updates, including base salaries, bonuses, equity awards, and director compensation policy changes. There is no detailed financial performance data, earnings information, or full report content. The primary subject is changes in compensation and board-related matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board-related decisions. The document length (6254 characters) and detailed compensation data support this classification rather than a brief announcement or a full annual/interim report.
2023-03-10 English
Director's Dealing 2023
Director's Dealing
2023-03-09 English
Director's Dealing 2023
Director's Dealing
2023-03-09 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.